Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen's Already Competitive

Executive Summary

Retacrit – a biosimilar of Amgen's Epogen and J&J's Procrit – will launch at aggressive discounts to the original anemia products in a market where Amgen's already proven there's a tough fight for market share.

Advertisement

Related Content

Coherus Gears Up For January Udenyca Launch, Prices Biosimilar At 33% Discount To Neulasta
J&J Well Positioned For US Drug Pricing Changes Regardless Of Timing Or Form, Duato Says
From Interchangeability To Exclusivity: US FDA Looks For Ways To Make Biologics Market More Competitive
Pfizer Wants FDA To Stop Sponsor Promos From Implying Biosimilars Are Inferior
FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts
Vifor Becomes A 'Pure Play' Pharma
Pfizer Will Support Inflectra Launch With Dedicated Sales Force
Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124172

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel